% | $
Quotes you view appear here for quick access.

SIGA Technologies Inc. Message Board

nicehedges 3 posts  |  Last Activity: Apr 25, 2016 7:27 PM Member since: Feb 15, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    For Anyone Who's Interested

    by oosetrain760 Apr 25, 2016 10:07 AM
    nicehedges nicehedges Apr 25, 2016 7:27 PM Flag

    definitely impressive. nice find.

  • NEW YORK --(BUSINESS WIRE)-- SIGA Technologies, Inc a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, announced today that it has begun enrolling the second and final cohort of healthy subjects for the Phase III clinical study for its lead drug candidate, TPOXX (tecovirimat), for the treatment of orthopoxvirus. This Phase III study, which is wholly funded the by the Biomedical Advanced Research and Development Authority (BARDA) will be conducted at eleven approved investigative sites with a total of approximately 360 subjects.
    The initial Phase III lead cohort of 40 subjects in this trial has already completed participation without any reports of serious adverse events.
    Screening of subjects for the second Phase III cohort initiated on April 11, 2016 , and the first subject was enrolled and dosed on April 18, 2016 . Since tecovirimat is being developed under the FDA "Animal Rule," there are no efficacy endpoints in this clinical trial. This study will generate safety and pharmacokinetic data in support of the prescribing information that will be part of the New Drug Application (NDA) filing.

  • Reply to

    TD says SIGAQ no longer exists

    by acs.chuckie Apr 18, 2016 8:33 AM
    nicehedges nicehedges Apr 18, 2016 10:14 AM Flag

    now trading under SIGA

0.690.0000(0.00%)May 24 3:49 PMEDT